Recombinant full-length parathyroid hormone (1-84): A viewpoint by David A. Hanley

Drugs

Volumn 66, Issue 18, 2006, Pages 2382-

  Hanley, David A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID;

BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; NONHUMAN; NOTE; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 33846112018     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666180-00010     Document Type: Note

References (2)

1. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26 (5): 688-703
2. Hodsman A, Papaioannou A, Cranney A. Scientific Advisory Council of Osteoporosis Canada, Clinical Guidelines Committee, Writing Group on the Systematic Review of Parathyroid Hormone for the Treatment of Osteoporosis. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 2006 Jul 4; 175 (1): 48